Akeso Biopharma, Inc.

Waterstone Pharmaceuticals(wuhan) Co., Ltd.

Taizhou Hanzhong Biopharmaceutics, Inc.

Hanx Biopharmaceutics, Inc

The General Hospital Corporation

Waterstone Pharmaceuticals Co., Ltd.

Faming Zhang

Ying Huang

Gan Xi

Yu Xia

Baiyong Li

Zhongmin Maxwell Wang

Yan Li

Jian Cui

Minglong Hu

Xiaoyu Liu

Yao Yu

Lina Qian

Zhongcong Xie

Tongtong Li

Kang Bie

Ying Liang

Youcheng Zhou

Hang Ke

Huojian Wang

Yuan Meng

Zhengwen Leng

Sihan Zhang

Huiling Tang

Min Fu

The disclosure provides polymers and compositions thereof, as well as methods for preparing such polymers and compositions. Also provided is a method of using the polymers or compositions thereof for binding uric acid or precursor thereof, and/or for treating hyperuricemia, gout, and/or diseases caused by hyperuricemia.

Polymers, compositions and methods for treating hyperuricemia

The present invention relates to a method of treating, preventing, or lessening postoperative cognitive dysfunction (POCD) in a subject in need thereof, the method comprising the step of administering to the subject a therapeutically effective amount of a compound of Formula I or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof,

WS-635 uses thereof in medicine

Provided in the present invention are an anti-OX40 monoclonal antibody or an antigen-binding fragment thereof, and a corresponding isolated polynucleotide, expression vector, recombinant cell, pharmaceutical composition, and application thereof. The present antibody can be used for the treatment of cancer or autoimmune disease.

Anti-OX40 monoclonal antibody and application thereof

The present invention provides a recombinant protein. The recombinant protein includes an anti-PD-1 antibody and human SIRPA extracellular domain. The N-terminus of the human SIRPA extracellular domain is linked to the C-terminus of the heavy chain of the anti-PD-1 antibody.

Anti-PD-1/CD47 bispecific antibody and application thereof

Proposed is an anti-PD-1 monoclonal antibody or an antigen binding fragment thereof, comprising a heavy chain variable region having at least one of the amino acid sequences listed below: (1) the amino acid sequence shown in SEQ ID NO: 1; (2) the amino acid sequence shown in SEQ ID NO: 3; (3) the amino acid sequence shown in SEQ ID NO: 5; and (4) an amino acid sequence having more than one conservative amino acid mutation compared with (1)-(3).

Anti-PD-1 monoclonal antibody

Provided is a monoclonal antibody against programmed death-1 (PD-1) or applications thereof, where the monoclonal antibody against PD-1 comprises a neonatal Fc Receptor (FcRn)-binding site having an amino acid sequence of SEQ ID NO: 5.

Monoclonal antibody against PD-1 and application thereof

Growing community of inventors

Hubei, China

Faming Zhang